Dana-Farber Cancer Institute
Harvard Medical School

Boston, Massachusetts
Professor, Department of Cancer Immunology at the Dana-Farber Cancer Institute
Professor of Medicine, Department of Medicine at Harvard Medical School

Research

Dr. Marasco is developing immunotherapy for cancer. He is a pioneer in engineering a patient’s immune system T cells to express new targeting receptors – liken to antennas on cells – that can seek out and kill cancer. As a type of adoptive cell therapy using a patient’s own immune cells, this specific modification of the patient’s T cells is referred to as Chimeric Antigen Receptor (CAR) T cell therapy. CAR-T therapy not only initiates the killing of a patient’s cancer, but also stimulates the patient’s immune system to activate more T cells within the body to seek and kill cancer. While CAR-T therapy has been approved for types of blood cancers, lymphoma and leukemia, it has not been successful in treating solid tumors.

With NFCR support since 1994, Dr. Marasco has advanced his immunotherapy for clear cell renal cell carcinoma, a type of kidney cancer among the ten most common cancers in men and women. His approach combines CAR-T therapy with checkpoint blockade inhibitors or antibodies that stimulate the immune system. This combination approach is designed to change the tumor environment and enhance the ability of CAR-T treatment to kill cancer cells. Dr. Marasco has proven that restoring the tumor environment towards effective T cell anti-tumor immunity leads to significant renal cell carcinoma cell death in complex tumor models. His technology may be a breakthrough for patients with renal cell carcinoma and may serve as a platform therapy to treat all solid tumors.

Bio

Wayne Marasco, M.D., Ph.D., studied at the University of Connecticut’s School of Medicine, where he received his Ph.D. in 1980. He conducted his postdoctoral training at the University of Michigan Medical School, where he also earned a M.D. in 1986. He received his sub-specialty training in infectious diseases at Harvard Medical School, where he is currently a professor, and he joined the Dana-Farber Cancer Institute in 1989. In 1992, he also joined the Division of Infectious Diseases at Brigham and Women’s Hospital.

In 1980 and 1981, Dr. Marasco won the Biomedical Research Council Award and the National Research Service Award from the University of Connecticut School of Medicine, and the University of Michigan awarded him the United States Public Health Service Award in 1981, the Dean’s Award for Research Excellence in 1986 and the Lung Immunopathology Training Grant Award in 1987 and 1988.

Dr. Marasco served as the Director of the NFCR Center for Therapeutic Antibody Engineering from 2003 to 2017 to expand the use of human monoclonal antibodies in the treatment of cancer. In 2009, U.S. News & World Report listed Dr. Marasco as a “Medical Pioneer” and a top scientist in his field. In the same year, Dr. Marasco was selected as a Distinguished Speaker by the Walter Reed Army Institute of Research.

Related Content

NFCR In the News: Addressing Deadly Brain Cancer, GBM

New Treatment & Renewed Hope for Triple-negative Breast Cancer Patients

Efficiently Eliminating Metastasized Melanoma Cells

The prevalence of skin cancer is rising at an alarming rate, with melanoma being the deadliest. Melanoma is renowned for quickly spreading to other organs (or metastasizing), drastically decreasing the likelihood of survival. Being able to stop the spread of melanoma cells is essential to save the lives of many patients; however, no researcher has been able to solve the puzzle – until now. With long-term support from the National Foundation for Cancer Research (NFCR), Dr. Daniel Haber and his team developed the CTC-iChip – a medical device to capture the few circulating tumor cells (CTCs) present in a standard blood sample from a patient. Circulating tumor cells are tumor cells that have become detached from the primary tumor and enter the blood circulation. While CTCs occur once in a billion cells and are extremely rare, they nevertheless may hold the key to metastasis—the stage responsible for most cancer deaths. Dr. Haber and his team developed methods to analyze the genes in CTCs, providing a liquid biopsy and an invaluable window into a patient’s cancer in real-time. Doctors may efficiently obtain critical information from their patient’s CTCs for life-saving treatment decisions in advanced cancer with the liquid biopsy. Though this significant breakthrough sparked excitement throughout the oncology world, Dr. Haber continued digging for more pieces to the puzzle. He honed in on the unique makeup of CTCs to understand what fueled the spread of these deadly cells and what inhibited it. Using samples from melanoma patients, the team found that the unique lipogenesis regulator (referred to as SREBP2) held an important role in combating the growth of CTCs. SREBP2 directly induces transcription of the iron carrier, which kicks off a chain reaction at a cellular level. This chain reaction causes resistance to ferroptosis inducers, a type of programmed cell death. The ability to manufacture these chain reactions within CTCs opens up a realm of therapeutic opportunities for patients with metastatic melanoma. While this discovery is highly significant in the war on cancer, it is only just the beginning of understanding how to reduce melanoma metastasis. Dr. Haber remains committed to solving more pieces of the puzzle. To support the work of Dr. Haber and other world-renowned researchers, please make a gift today. Additional Reads You May Enjoy: New Drug Makes Unresectable or Metastatic Ocular Cancer Treatable Catching Cancer Cells on Their Way to Spreading Detecting Skin Cancer with Artificial Intelligence and Other Game-Changing Technologies in Cancer Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.